- Home
- HUBB vs BIIB Comparison
HUBB vs BIIB Comparison
Compare HUBB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBB
- BIIB
- Stock Information
- Founded
- HUBB 1888
- BIIB 1978
- Country
- HUBB United States
- BIIB United States
- Employees
- HUBB N/A
- BIIB N/A
- Industry
- HUBB Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- HUBB Technology
- BIIB Health Care
- Exchange
- HUBB Nasdaq
- BIIB Nasdaq
- Market Cap
- HUBB 23.2B
- BIIB 25.1B
- IPO Year
- HUBB N/A
- BIIB 1991
- Fundamental
- Price
- HUBB $430.40
- BIIB $149.90
- Analyst Decision
- HUBB Hold
- BIIB Buy
- Analyst Count
- HUBB 8
- BIIB 26
- Target Price
- HUBB $472.13
- BIIB $248.00
- AVG Volume (30 Days)
- HUBB 344.3K
- BIIB 1.5M
- Earning Date
- HUBB 01-28-2025
- BIIB 02-11-2025
- Dividend Yield
- HUBB 1.22%
- BIIB N/A
- EPS Growth
- HUBB 8.35
- BIIB 10.05
- EPS
- HUBB 13.89
- BIIB 11.06
- Revenue
- HUBB $5,640,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- HUBB $8.17
- BIIB N/A
- Revenue Next Year
- HUBB $5.08
- BIIB N/A
- P/E Ratio
- HUBB $30.99
- BIIB $13.55
- Revenue Growth
- HUBB 7.50
- BIIB N/A
- 52 Week Low
- HUBB $315.38
- BIIB $145.07
- 52 Week High
- HUBB $481.35
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- HUBB 39.80
- BIIB 35.04
- Support Level
- HUBB $418.82
- BIIB $145.07
- Resistance Level
- HUBB $459.94
- BIIB $149.92
- Average True Range (ATR)
- HUBB 10.07
- BIIB 3.71
- MACD
- HUBB -3.09
- BIIB 0.26
- Stochastic Oscillator
- HUBB 21.98
- BIIB 30.65
About HUBB Hubbell Inc
Hubbell is a diversified conglomerate industrial company that mostly competes in the electrical components market. Its products and services serve vital portions of the U.S. electrical supply chain, including transmission and distribution as well as the commercial, industrial, and residential end markets. The company organizes its business into two segments: Utility Solutions Segment and the Electrical Solutions Segment. It derives maximum revenue from Utility Solutions Segment.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.